Patents by Inventor Jason Gall
Jason Gall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10493144Abstract: The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.Type: GrantFiled: January 17, 2019Date of Patent: December 3, 2019Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Justin Widener, Leszlie Woodyard, Leonardo Siger, Douglas Brough, Damodar Ettyreddy, Jason Gall, Duncan McVey, Tom Burrage, Lauri Motes-Kreimeyer, Marc Fiorucci
-
Publication number: 20190134183Abstract: The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.Type: ApplicationFiled: January 17, 2019Publication date: May 9, 2019Inventors: Justin WIDENER, Leszlie Woodyard, Leonardo Siger, Douglas Brough, Damodar Ettyreddy, Jason Gall, Duncan McVey, Tom Burrage, Lauri Motes-Kreimeyer, Marc Fiorucci
-
Patent number: 10188721Abstract: The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.Type: GrantFiled: January 30, 2017Date of Patent: January 29, 2019Assignee: Merial, Inc.Inventors: Justin Widener, Leszlie Woodyard, Leonardo Siger, Douglas Brough, Damodar Ettyreddy, Jason Gall, Duncan McVey, Tom Burrage, Lauri Motes-Kreimeyer, Marc Fiorucci
-
Publication number: 20170216422Abstract: The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.Type: ApplicationFiled: January 30, 2017Publication date: August 3, 2017Applicants: MERIAL INC., Genvec Inc., THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary of Homeland SecurityInventors: Justin Widener, Leszlie Woodyward, Leonardo Siger, Douglas Brough, Damodar Ettyreddy, Jason Gall, Duncan McVey, Tom Burrage
-
Patent number: 9586998Abstract: The invention provides methods for propagating a monkey adenovirus in a cell, including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus, including a replication-deficient monkey adenovirus, obtained by such propagation methods.Type: GrantFiled: August 4, 2015Date of Patent: March 7, 2017Assignee: GenVec, Inc.Inventors: Jason Gall, Douglas Brough, Christoph Kahl, Duncan McVey
-
Publication number: 20150329834Abstract: The invention provides methods for propagating a monkey adenovirus in a cell, including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus, including a replication-deficient monkey adenovirus, obtained by such propagation methods.Type: ApplicationFiled: August 4, 2015Publication date: November 19, 2015Applicant: GenVec, Inc.Inventors: Jason Gall, Douglas Brough, Christoph Kahl, Duncan McVey
-
Patent number: 9133248Abstract: The invention provides methods for propagating a monkey adenovirus in a cell including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus. including a replication-deficient monkey adenovirus, obtained by such propagation methods.Type: GrantFiled: November 9, 2010Date of Patent: September 15, 2015Assignee: GenVec, Inc.Inventors: Jason Gall, Douglas Brough, Christoph Kahl, Duncan McVey
-
Publication number: 20120225470Abstract: The invention provides methods for propagating a monkey adenovirus in a cell including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus. including a replication-deficient monkey adenovirus, obtained by such propagation methods.Type: ApplicationFiled: November 9, 2010Publication date: September 6, 2012Applicant: Genvec, Inc.Inventors: Jason Gall, Douglas Brough, Christoph Kahl, Duncan McVey
-
Publication number: 20080069836Abstract: The invention provides a method of inducing an immune response in a mammal. The method comprises administering to the mammal an adenoviral vector comprising (a) a subgroup C fiber protein wherein a native coxsackievirus and adenovirus receptor (CAR)-binding site is disrupted, (b) a subgroup C penton base protein wherein a native integrin-binding site is disrupted, and (c) a nucleic acid sequence encoding at least one antigen derived from an infectious agent other than an adenovirus which is expressed in the mammal to induce an immune response.Type: ApplicationFiled: February 26, 2007Publication date: March 20, 2008Applicants: The Government of the U.S.A., as represented by the Secretary, Department of Health and Human Ser, and Human Services, GenVec, Inc., GenVec, Inc.Inventors: Gary Nabel, Cheng Cheng, Jason Gall, Thomas Wickham
-
Publication number: 20080003236Abstract: The invention provides a gene transfer vector and a conjugate comprising at least three contiguous amino acids of a shaft region of a subgroup C adenovirus fiber protein. The invention also provides methods of using the gene transfer vector and the conjugate to induce an immune response in a mammal, and to deliver a protein or a non-proteinaceous molecule to a specific cell type.Type: ApplicationFiled: April 13, 2007Publication date: January 3, 2008Applicants: GenVec, Inc., Government of the U.S.A., represented by the Secretary, Department of Health and Human ServicesInventors: C. King, Jason Gall, Gary Nabel, Cheng Cheng
-
Publication number: 20070207166Abstract: The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune response against HIV in the mammal. The invention also provides an adenoviral vector composition comprising four adenoviral vectors encoding an HIV clade A Env protein, an HIV clade B Env protein, an HIV clade C Env protein, and a fusion protein comprising an HIV clade B Gag protein and Pol protein, respectively.Type: ApplicationFiled: April 12, 2005Publication date: September 6, 2007Applicant: GenVec, Inc.Inventors: Gary Nabel, Cheng Cheng, Wing-Pui Kong, Jason Gall, C. Richter King
-
Publication number: 20060286121Abstract: The invention provides a method of inducing an immune response in a mammal. The method comprises administering to the mammal a non-subgroup C adenoviral vector comprising an adenoviral fiber protein having an amino acid sequence comprising about 80% or more identity to an amino acid sequence encoding a subgroup C adenoviral fiber protein. The adenoviral vector further comprises a nucleic acid sequence encoding an antigen which is expressed in the mammal to induce an immune response. The invention further comprises a method of producing an adenoviral vector, and a composition comprising a serotype 41 or a serotype 35 adenoviral vector and a carrier. The invention also provides an adenoviral vector comprising a nucleic acid sequence encoding an adenoviral pIX protein operably linked to a heterologous expression control sequence, as well as a method of enhancing the stability and/or packaging capacity of an adenoviral vector.Type: ApplicationFiled: January 23, 2006Publication date: December 21, 2006Inventors: Jason Gall, Thomas Wickham, William Enright, Douglas Brough, Mohammed Zuber, C. King, Gary Nabel, Cheng Cheng
-
Publication number: 20060140909Abstract: The invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises slowly releasing into the bloodstream a dose of replication-deficient or conditionally-replicating adenoviral vector having reduced ability to transduce mesothelial cells and hepatocytes. The normalized average bloodstream concentration of the adenovirus over 24 hours post-administration is at least about 1%. Alternatively, the normalized average bloodstream concentration over 24 hours post-administration is at least about 5-fold greater than the normalized average bloodstream concentration for an equivalent dose of a wild-type adenoviral vector. A method of destroying tumor cells in a mammal also is provided, as is a replication-deficient adenoviral vector comprising a serotype 5 or serotype 35 adenoviral genome with a serotype 41 fiber protein, wherein the replication-deficient adenoviral vector exhibits reduced native binding to integrins.Type: ApplicationFiled: August 19, 2005Publication date: June 29, 2006Applicants: GenVec, Inc., FUSO Pharmaceutical Industries, Ltd.Inventors: Thomas Wickham, Masaki Akiyama, Jason Gall
-
Publication number: 20050063953Abstract: The invention provides an adenoviral vector comprising (a) at least a portion of an adenoviral genome comprising a major late transcription unit containing a terminal exon, wherein the terminal exon comprises a 5? splice acceptor DNA sequence element and a 3? polyadenylation signal sequence, and (b) a non-native nucleic acid sequence encoding a protein that does not contribute to the adenoviral vector entry into a host cell, wherein the non-native nucleic acid sequence is positioned within the terminal exon, such that the non-native nucleic acid sequence is selectively expressed in cells within which the adenoviral vector can replicate. The invention further provides an adenoviral vector composition and a method for treating or preventing a pathologic state in a mammal, comprising administering to the mammal the adenoviral vector composition of the invention in an amount sufficient to treat or prevent the pathologic state in the mammal.Type: ApplicationFiled: August 5, 2004Publication date: March 24, 2005Applicant: Cornell Research Foundation, Inc.Inventors: Erik Falck-Pedersen, Jason Gall
-
Publication number: 20030166286Abstract: A recombinant adenovirus comprising a chimeric adenoviral fiber protein comprising a non-adenoviral amino acid sequence in place of or in addition to a native fiber amino acid sequence, wherein the chimeric adenoviral fiber protein comprises a trimerization domain and the non-adenoviral amino acid sequence is of a size such that folding of the chimeric adenoviral fiber protein and assembly of a complex comprising the chimeric adenoviral fiber protein and a penton base is not impeded, and an adenoviral transfer vector for the generation of such a recombinant adenovirus are provided.Type: ApplicationFiled: June 17, 2002Publication date: September 4, 2003Applicant: Cornell Research Foundation, Inc.Inventors: Thomas J. Wickham, Erik Falck-Pedersen, Petrus W. Roelvink, Joseph T. Bruder, Jason Gall, Imre Kovesdi
-
Patent number: 6576456Abstract: The invention provides a chimeric adenovirus fiber protein including a nonnative amino acid sequence, and a chimeric adenovirus fiber protein lacking a native amino acid receptor-binding sequence. The chimeric protein trimerizes when produced in a mammalian cell.Type: GrantFiled: June 4, 1999Date of Patent: June 10, 2003Assignees: Cornell Research Foundation, Inc., GenVec, Inc.Inventors: Thomas J. Wickham, Erik Falck-Pedersen, Petrus W. Roelvink, Joseph T. Bruder, Jason Gall, Imre Kovesdi
-
Publication number: 20020099024Abstract: The invention provides a chimeric adenovirus fiber protein including a nonnative amino acid sequence, and a chimeric adenovirus fiber protein lacking a native amino acid receptor-binding sequence. The chimeric protein trimerizes when produced in a mammalian cell.Type: ApplicationFiled: June 4, 1999Publication date: July 25, 2002Inventors: THOMAS J. WICKHAM, ERIK FALCK-PEDERSEN, PETRUS W. ROELVINK, JOSEPH T. BRUDER, JASON GALL, IMRE KOVESDI
-
Patent number: 6153435Abstract: The present invention provides a chimeric adenoviral coat protein (particularly a chimeric adenovirus hexon and/or fiber protein). The chimeric adenovirus coat protein has a decreased ability or inability to be recognized by a neutralizing antibody directed against the corresponding wild-type adenovirus coat protein. The invention also provides an adenovirus comprising a chimeric adenovirus coat protein, and methods of constructing and using such an adenovirus, for instance, in gene therapy.Type: GrantFiled: June 17, 1999Date of Patent: November 28, 2000Assignees: Cornell Research Foundation, Inc., GenVec, Inc.Inventors: Ronald G. Crystal, Erik Falck-Pedersen, Jason Gall, Imre Kovesdi, Thomas J. Wickham
-
Patent number: 6127525Abstract: The present invention provides a chimeric adenoviral coat protein (particularly a chimeric adenovirus hexon and/or fiber protein). The chimeric adenovirus coat protein has a decreased ability or inability to be recognized by a neutralizing antibody directed against the corresponding wild-type adenovirus coat protein. The invention also provides an adenovirus comprising a chimeric adenovirus coat protein, and methods of constructing and using such an adenovirus, for instance, in gene therapy.Type: GrantFiled: March 13, 1997Date of Patent: October 3, 2000Assignees: Cornell Research Foundation, Inc., GenVec, Inc.Inventors: Ronald G. Crystal, Erik Falck-Pedersen, Jason Gall, Imre Kovesdi, Thomas J. Wickham
-
Patent number: 5770442Abstract: A recombinant adenovirus comprising a chimeric fiber protein and a therapeutic gene, a method of gene therapy involving the use of such an adenovirus, and an adenoviral transfer vector for the generation of such a recombinant adenovirus are provided.Type: GrantFiled: February 21, 1995Date of Patent: June 23, 1998Assignees: Cornell Research Foundation, Inc., GenVec, Inc.Inventors: Thomas J. Wickham, Erik Falck-Pedersen, Petrus W. Roelvink, Joseph T. Bruder, Jason Gall, Imre Kovesdi